PVLA (45) IMNM (26) PRGO (49) SEPN (63) ⌘ Pro Terminal →

Lakefront Biotherapeutics (LKFT) — RQD Stock Rating Cockpit

$32.28 -0.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $32.21

Lakefront Biotherapeutics (LKFT) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $2.13B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LKFT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LKFT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Lakefront Biotherapeutics (NASDAQ: LKFT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $32.28 (-0.15% 1D, market cap $2.13B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LKFT ranks #191 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LKFT compare to PVLA and IMNM in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LKFT carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PVLA (Palvella Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -27.9%, cap $2.11B) and IMNM (Immunome Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.15B). Among the 5-stock peer group, LKFT leads on earnings multiple (N/A) while PRGO leads on capital efficiency (-13.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LKFT?

▼

For Lakefront Biotherapeutics (LKFT), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #191 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $32.21 (-0.22%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LKFT)Realized 20D OHLCV Swing Band: ±4.8%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY LKFT SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (21% of score)

SEC XBRL Trailing 12 Months: 1.5% FCF Margin ($59.6M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$29.05+5.9% Next Q

Q2 (-2Q)

Grade C-$30.75+3.5% Next Q

Q3 (-1Q)

Grade C-$31.82+1.4% Next Q

Current

Grade D+$32.28-0.2% Hist 90D α

Trajectory: D (49) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LKFT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, LKFT faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($29.62) or 200D SMA ($29.91) invalidates the momentum regime and cuts Target Base ($32.13) toward Bear Floor ($25.06).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LKFT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LKFT Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

69.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE63% OF RANGE

L: $26$32.28H: $36

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D+RQD 21 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on LKFT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (53)

21/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like LKFT

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LKFT)

✓Walkthrough of LKFT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LKFT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +13.42%▲ ASCENDING CHANNEL

2026-11-03O $32.33H $32.33L $32.28C $32.28VOL 164.1K

RES: $33.25SUP: $27.86SMA50: $29.62SMA200: $29.91

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LKFT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LKFT Butterfly Map → + Track LKFT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LKFT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LKFT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LKFT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LKFT)

Health Care Rank #191 of 1016 ⚔️ PVLA vs LKFT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LKFT vs. PVLA, IMNM, PRGO, SEPN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lakefront Biotherapeutics (LKFT) ranks #191 by composite RQD confidence (57/100, grade D+) and #245 by equity capitalization ($2.13B). Within this direct 5-issuer industry benchmark cohort, LKFT leads on earnings valuation at N/A trailing P/E, while PRGO leads on capital efficiency and profitability with -13.6% ROIC and 35.1% gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with LKFT at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LKFT ACTIVE Lakefront Biotherapeutics	D+	57/100	—	—	—	-0.15%	$2.13B	Benchmark Subject
PVLA Palvella Therapeutics Inc.	D	45/100	—	—	-27.9%	-3.58%	$2.11B	/pvla-vs-lkft →
IMNM Immunome Inc.	E	26/100	—	—	-35.0%	-0.44%	$2.15B	/imnm-vs-lkft →
PRGO Perrigo Company plc	D	49/100	—	35.1%	-13.6%	-0.75%	$2.19B	/prgo-vs-lkft →
SEPN Septerna Inc.	C	63/100	—	—	-20.7%	-2.72%	$2.05B	/sepn-vs-lkft →

2. LKFT Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Lakefront Biotherapeutics (LKFT) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $2.13B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. LKFT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LKFT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LKFT compare to PVLA and IMNM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LKFT?

Where is LKFT trading relative to its 50-day, 200-day, and 52-week technical levels?

LKFT last traded at $32.28 (-0.15% on volume of 164,059 shares), positioning the stock +8.98% above its 50-day simple moving average ($29.62) and +7.92% above its 200-day simple moving average ($29.91). Across its 52-week range of $25.68 to $36.24, LKFT sits at the 62.5% percentile with a 14-day RSI of 69.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.8% ($30.73 to $33.83).

LKFT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LKFT stock right now?

Lakefront Biotherapeutics (LKFT) currently earns a Roarable Rating of D+ (Sell — SELL) with 57/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is LKFT's 12-month price target and RQD AI Jury consensus?

LKFT's 12-month base price target is $32.13 (range $25.06 to $38.05), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LKFT RQD Cockpit LKFT 12M Forecast LKFT Earnings & Move LKFT Dividends & DRIP LKFT Insiders & 13F LKFT Whale Options LKFT Profit Sankey LKFT News & Why

ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LKFT — Lakefront Biotherapeutics: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:12:38Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LKFT scores 56 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars break down as follows. Fundamental Cash Engine scores 12 of 20, with ROIC at 0% and FCF yield at 0%, indicating the source data shows no measurable return on invested capital or free-cash-flow generation. Whale 13F Flow scores 12 of 20, reflecting institutional accumulation and options positioning. Insider Conviction scores 9 of 20, based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 10 of 20, with a Beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 13 of 20, reflecting an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the rating points to a mixed picture. The weakest pillar is insider conviction, and the cash-generation pillar is weak because the source data reports zero ROIC and zero FCF yield, which leaves valuation tradeoffs difficult to assess on earnings or cash-flow terms. The balance sheet pillar is the relative strength, with a Piotroski F of 6/9 and a Debt/Equity of 0.5. Beta of 1.0 implies the stock moves in line with the broader market per the source data, so macro sensitivity is not an outlier. Potential upside drivers in the source data are limited to the positive news items described below; the rating itself frames the overall posture as trim rather than accumulate.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the following items are listed:

RISK WATCH (RED): A Yahoo Finance report headlined that the stock "Looks Undervalued Despite A 40% Five Year Fall."
CATALYST (GREEN): A Yahoo Finance report headlined an upgrade to Buy for the sponsored ADR.
MARKET WIRE (YELLOW): A MarketBeat report indicates a "Hold" rating from Wall Street brokerages.
MARKET WIRE (YELLOW): A Morgan Stanley initiation with an Equalweight rating, reported by Investing.com India.
MARKET WIRE (YELLOW): A GlobeNewswire release titled "Acquisition of Own Shares."
MARKET WIRE (YELLOW): A MarketBeat short-interest report for October.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no upstream or downstream dependencies, no sector correlations, and no proprietary signals provided. Not available in source data for upstream/downstream dependencies, sector correlations, or 2nd-order bottlenecks.

Open Questions

What are the company's reported revenue, earnings, and cash-flow figures for any period, given that the financials section is listed as NONE?
What is the current P/E, EPS, and EV/EBITDA, given that these fields are marked not available in source data?
What is the basis for the "Acquisition of Own Shares" release, and what is its size and stated purpose?
What does the source data show regarding the company's pipeline, products, or clinical catalysts, which are not described in the profile?
What are the specific analyst price targets and insider or 13F holder positions, given that those sections are listed as NONE?

LKFT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lakefront Biotherapeutics (LKFT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LKFT Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 17h ago

Lakefront Biotherapeutics (ENXTAM:LKFT) Stock Looks Undervalued Despite A 40% Five Year Fall

Yahoo Finance report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 20h ago

Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?

Yahoo Finance report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 23h ago

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Now Rated "Hold" by Wall Street Brokerages

MarketBeat report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com India • 1d ago

Morgan Stanley initiates Lakefront Biotherapeutics stock with Equalweight rating

Investing.com India report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Acquisition of Own Shares

GlobeNewswire report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH TipRanks • 1d ago

Lakefront Biotherapeutics Discloses Bank of America Stake Cut Below 10% Threshold

TipRanks report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 10h ago

Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors

Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board Mechelen, Belgium; November 2, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext &

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 18d ago

Belgian startup revives Galapagos CAR-T research

Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LKFT Bull vs. Bear Conversation Board — What's Your Call at $32.28?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LKFT 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $34.92 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LKFT (D+ • RQD 56/100) a Buy at $32.33?

Welcome to the LKFT (Lakefront Biotherapeutics) Roar Pit. Current RQD Composite is 56/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $24.25 (-25.0%)

Spot @ $32.33

Pump the brakes on LKFT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LKFT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Lakefront Biotherapeutics expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $38.15 (+18.0%)

Spot @ $32.33

LKFT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LKFT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $32.33 (52-wk range $25.68 - $36.24), any beat on forward guidance forces shorts and underweight funds to chase.